HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
1 - 4 of 4
ANBL1232 Response & Biology Risk Factors in Patients with Non-High-Risk Neuroblastoma
In this study we are using new biologic features, in addition to the standard risk factors, to help decide which subjects need treatment and what the best treatment is.
Related PI: Rochelle Bagatell, MD
Related Conditions: Neuroblastoma, Pediatric Neurology, Oncology
The Myelin Disorders Biorepository Project (MDBP)
This study involves the collection of medical information and samples from people with a confirmed or suspected leukodystrophy or related disorder affecting the white matter of the brain, as well as "healthy controls" who are not known to be affected by one of these disorders.
Related PI: Adeline L. Vanderver, MD
Related Conditions: Leukodystrophies, Leukodystrophy, Biorepository, Pediatric Neurology, Neurological and Neuromuscular , Genetic Disease, Genetic Disorders, Rare Genetic Disorders, Pediatric Genetic Disease, Aicardi Goutieres Syndrome, TUBB4A, Metachromatic Leukodystrophy, Adrenoleukodystrophy, Leukoencephalopathies, Leukoencephalopathy, Biobank, Biobanking, H-ABC, Alexander Disease, Krabbe Disease, Whole Genome Sequencing, Exome Sequencing, Whole Exome Sequencing, Next Generation DNA/RNA Sequencing, Next-generation Sequencing, Rare Disorder Natural History Studies, Rare Disease
Trial of Erenumab for Preventive Treatment of Pediatric migraine 15 days per month or more
This study is a trial comparing the effects of erenumab to placebo in children ages 6-17 years old with migraine 15 days per month or more.
Related Conditions: Pediatric Neurology, Neurologic Function
Trial of Erenumab in Children and Teens with Migraine less than 15 days per month
This study is a trial comparing the effects of erenumab to placebo in children ages 6-17 years old with migraine less than 15 days per month.
Related Conditions: Pediatric Neurology, Neurologic Function